Mani Inc
TSE:7730
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 063.5
1 880
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Mani Inc
In the dynamic landscape of modern manufacturing, Mani Inc. emerges as a pivotal player, weaving together innovation and tradition in the realm of precision tools. Founded in the late 20th century, the company quickly distinguished itself by specializing in the design and production of high-quality dental and medical instruments. At its core, Mani Inc. thrives on its commitment to quality and reliability, underpinning its operations with cutting-edge technology and meticulous craftsmanship. Boasting a global presence, the company navigates a complex supply chain and adheres to stringent regulatory standards, ensuring its tools meet the diverse needs of practitioners around the world. Mani Inc. engages directly with dental professionals and healthcare institutions, building lasting relationships that are strengthened by the consistent performance and longevity of its products.
Economically, Mani Inc. capitalizes on its expansive distribution network and brand loyalty to generate revenue, with a business model that focuses on both direct sales and partnerships with distributors. This approach allows the company not only to reach a wide array of international markets but also to tailor its offerings to specific regional demands. Its commitment to research and development propels innovation that further solidifies its market position, helping to safeguard against the fluctuations that often characterize the medical tools segment. By investing significantly in R&D, Mani Inc. ensures its product lineup remains at the forefront of technology and efficiency, thereby reinforcing its competitive edge in an industry where precision is paramount.
In the dynamic landscape of modern manufacturing, Mani Inc. emerges as a pivotal player, weaving together innovation and tradition in the realm of precision tools. Founded in the late 20th century, the company quickly distinguished itself by specializing in the design and production of high-quality dental and medical instruments. At its core, Mani Inc. thrives on its commitment to quality and reliability, underpinning its operations with cutting-edge technology and meticulous craftsmanship. Boasting a global presence, the company navigates a complex supply chain and adheres to stringent regulatory standards, ensuring its tools meet the diverse needs of practitioners around the world. Mani Inc. engages directly with dental professionals and healthcare institutions, building lasting relationships that are strengthened by the consistent performance and longevity of its products.
Economically, Mani Inc. capitalizes on its expansive distribution network and brand loyalty to generate revenue, with a business model that focuses on both direct sales and partnerships with distributors. This approach allows the company not only to reach a wide array of international markets but also to tailor its offerings to specific regional demands. Its commitment to research and development propels innovation that further solidifies its market position, helping to safeguard against the fluctuations that often characterize the medical tools segment. By investing significantly in R&D, Mani Inc. ensures its product lineup remains at the forefront of technology and efficiency, thereby reinforcing its competitive edge in an industry where precision is paramount.
Recall Impact: MANI's voluntary recall of DIA-BURS in China is expected to reduce full-year sales by JPY 1.52 billion and operating profit by JPY 1.2 billion, with the recall to be completed by August.
Guidance Cut: Fiscal year 2025 revenue forecast was revised down from JPY 8.0 billion to JPY 7.7 billion for China due to higher-than-expected recall volume.
Full-Year Forecast: The company now expects JPY 29.6 billion in net sales, JPY 7.9 billion in operating income, and JPY 5.45 billion in net income for fiscal year 2025.
Segment Performance: Surgical segment sales rose 16% and Eyeless Needle sales rose 6%, while Dental segment sales fell 10% year-on-year due to the recall.
Tariff Headwinds: A new 20% US tariff on Vietnamese shipments is expected to impact about 40% of US sales, with a JPY 40 million hit estimated.
Growth Initiatives: Strong growth seen in Russia, India, Central and South America; strengthened US presence through a new subsidiary and partnership with MST.
Medium-Term Plan: The next management plan will be announced October 8, 2025.
